About this data
What it is
The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
Who files it
The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
How current
We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
Terms
openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
Worth knowing
This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
Not to be confused with
Clinical trial updates: what sponsors report about their studies, not what the FDA decided.

All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.

FDA decisions per day, last 30 days

010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0
010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0

Brand-name drugs and biologics, with supplements Device clearances and approvals

By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.

Latest FDA decisions

Reset

Showing: ticker TAK · Everything

Latest FDA decisions
DecidedProductApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.FDA page
Oct 14, 2026LIALDA, MESALAMINE
MESALAMINE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA022000 ↗
Oct 14, 2026PENTASA
MESALAMINE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA020049 ↗
Aug 28, 2026MIMRYLO
RUSFERTIDE ACETATE
TAK
Takeda Pharmaceuticals Am
New drug (NDA)
Type 1 - New Molecular Entity
NDA220605 ↗
Aug 26, 2026GATTEX
TEDUGLUTIDE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
REMS
NDA203441 ↗
Aug 11, 2026KAZANO, ALOGLIPTIN AND METFORMIN HYDROCHLORIDE
ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA203414 ↗
Aug 11, 2026ACTOPLUS MET
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA021842 ↗
Aug 5, 2026ORZEYFUL
OVEPOREXTON
TAK
Takeda Pharmaceuticals USA
New drug (NDA)
Type 1 - New Molecular Entity
NDA220860 ↗
Apr 23, 2026VYVANSE
LISDEXAMFETAMINE DIMESYLATE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA208510 ↗
Letter or label ↗
Apr 23, 2026MYDAYIS
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMI…
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA022063 ↗
Letter or label ↗
Apr 23, 2026VYVANSE
LISDEXAMFETAMINE DIMESYLATE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA021977 ↗
Letter or label ↗
Apr 23, 2026DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTRO…
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMI…
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA021303 ↗
Letter or label ↗
Feb 25, 2026ENTYVIO, ENTYVIO PEN
VEDOLIZUMAB
TAK
Takeda Pharmaceuticals USA
Biologic (BLA), supplement
Labeling
BLA761133 ↗
Feb 25, 2026ENTYVIO
VEDOLIZUMAB
TAK
Takeda Pharmaceuticals USA
Biologic (BLA), supplement
Labeling
BLA125476 ↗
Nov 21, 2025LIVTENCITY
MARIBAVIR
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Efficacy
NDA215596 ↗
Oct 10, 2025ICLUSIG
PONATINIB HYDROCHLORIDE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Efficacy
NDA203469 ↗
Sep 23, 2025VYVANSE
LISDEXAMFETAMINE DIMESYLATE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA208510 ↗
Sep 23, 2025VYVANSE
LISDEXAMFETAMINE DIMESYLATE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA021977 ↗
Sep 23, 2025DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTRO…
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMI…
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA021303 ↗
Sep 5, 2025GATTEX
TEDUGLUTIDE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA203441 ↗
Aug 13, 2025GATTEX
TEDUGLUTIDE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
REMS
NDA203441 ↗
Jul 18, 2025HyHub™ and HyHub™ Duo Vial Access DevicesTAK
Takeda Pharmaceuticals
Device clearance (510(k))
Traditional
K243404 ↗
Jul 10, 2025MOTEGRITY
PRUCALOPRIDE SUCCINATE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Efficacy
NDA210166 ↗
Feb 28, 2025FRUZAQLA
FRUQUINTINIB
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA217564 ↗
Sep 19, 2024GATTEX
TEDUGLUTIDE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA203441 ↗
Letter or label ↗
Aug 29, 2024FOSRENOL
LANTHANUM CARBONATE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA204734 ↗
Letter or label ↗
Aug 29, 2024FOSRENOL, LANTHANUM CARBONATE
LANTHANUM CARBONATE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA021468 ↗
Letter or label ↗
Jul 30, 2024PENTASA
MESALAMINE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA020049 ↗
Jul 10, 2024VPRIV
VELAGLUCERASE ALFA
TAK
Shire Human Genetic
Biologic (BLA), supplement
Labeling
BLA022575 ↗
Jul 1, 2024NINLARO
IXAZOMIB CITRATE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA208462 ↗
Jun 28, 2024ALOGLIPTIN AND PIOGLITAZONE, OSENI
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA022426 ↗
Jun 28, 2024ACTOPLUS MET
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA021842 ↗
Letter or label ↗
May 16, 2024EOHILIA
BUDESONIDE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA213976 ↗
Apr 18, 2024ENTYVIO
VEDOLIZUMAB
TAK
Takeda Pharmaceuticals USA
Biologic (BLA)
Efficacy
BLA761359 ↗
Letter or label ↗
Apr 18, 2024ENTYVIO, ENTYVIO PEN
VEDOLIZUMAB
TAK
Takeda Pharmaceuticals USA
Biologic (BLA), supplement
Labeling
BLA761133 ↗
Letter or label ↗
Apr 18, 2024ENTYVIO, ENTYVIO PEN
VEDOLIZUMAB
TAK
Takeda Pharmaceuticals USA
Biologic (BLA), supplement
Labeling
BLA761133 ↗
Letter or label ↗
Apr 18, 2024ENTYVIO
VEDOLIZUMAB
TAK
Takeda Pharmaceuticals USA
Biologic (BLA), supplement
Labeling
BLA125476 ↗
Letter or label ↗
Apr 18, 2024ENTYVIO
VEDOLIZUMAB
TAK
Takeda Pharmaceuticals USA
Biologic (BLA), supplement
Labeling
BLA125476 ↗
Letter or label ↗
Mar 22, 2024LIVTENCITY
MARIBAVIR
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA215596 ↗
Mar 19, 2024ICLUSIG
PONATINIB HYDROCHLORIDE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Efficacy
NDA203469 ↗
Mar 14, 2024ENTYVIO, ENTYVIO PEN
VEDOLIZUMAB
TAK
Takeda Pharmaceuticals USA
Biologic (BLA), supplement
Labeling
BLA761133 ↗
Letter or label ↗
Mar 14, 2024ENTYVIO
VEDOLIZUMAB
TAK
Takeda Pharmaceuticals USA
Biologic (BLA), supplement
Labeling
BLA125476 ↗
Letter or label ↗
Mar 1, 2024NINLARO
IXAZOMIB CITRATE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA208462 ↗
Feb 23, 2024ENTYVIO, ENTYVIO PEN
VEDOLIZUMAB
TAK
Takeda Pharmaceuticals USA
Biologic (BLA), supplement
Labeling
BLA761133 ↗
Letter or label ↗
Feb 23, 2024ENTYVIO
VEDOLIZUMAB
TAK
Takeda Pharmaceuticals USA
Biologic (BLA), supplement
Labeling
BLA125476 ↗
Letter or label ↗
Feb 21, 2024GATTEX
TEDUGLUTIDE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Manufacturing (CMC)
NDA203441 ↗
Feb 9, 2024EOHILIA
BUDESONIDE
TAK
Takeda Pharmaceuticals USA
New drug (NDA)
Type 3 - New Dosage Form
NDA213976 ↗
Jan 19, 2024FIRAZYR
ICATIBANT ACETATE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Manufacturing (CMC)
NDA022150 ↗
Dec 12, 2023FOSRENOL
LANTHANUM CARBONATE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA204734 ↗
Letter or label ↗
Dec 12, 2023FOSRENOL, LANTHANUM CARBONATE
LANTHANUM CARBONATE
TAK
Takeda Pharmaceuticals USA
New drug (NDA), supplement
Labeling
NDA021468 ↗
Letter or label ↗
Nov 8, 2023FRUZAQLA
FRUQUINTINIB
TAK
Takeda Pharmaceuticals USA
New drug (NDA)
Type 1 - New Molecular Entity
NDA217564 ↗

The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 6:40 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates